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Automated Quantification of Creatine Kinase MB lsoenzyme in Serum by Radial Partition
Immunoassay, with Use of the Stratus Analyzer
Jean-Paul Chapelle end MagdelelneEl Allaf
We evaluated the analytical and clinical performances of a
new radial partition immunoassay for measunng the mass
concentration of creatine kinase (CK)-MB in serum. All
pipetting, washes, incubations and data reduction were per-
formed in 8 mm by the Stratus#{174}(Dade) fluorometric analyzer.
Within-assay and between-assay CVs were respectively
5.5% and 8.4% at 21 /L, and 4.2% and 3.4% at 48 /.Lg/L.
Assaying serial dilutions of serum samples with high CK-MB
concentrations demonstrated excellent linearity. Results of
the Stratus technique correlated well (n = 115, r = 0.98) with
those of the Tandem-E CKMB II assay. There was no
interference from hemolysis, bilirubin, rheumatoid factor, or
added CK-MM (up to 3500 U/L); consequently,CK-MB can
be determined in undiluted serum, even in the presence of
high total CK activity. The mean CK-MB concentration in 105
blood donors was 1.9 (SD 1.3) jg/L. For seven myocardial
infarction patients who received prompt fibrinolytic therapy,
the mean CK-MB concentration was 4.5 (SD 1.8) 1.ig/L at
admission, and maximum concentrations, 119 (SD 94) pg/L,
were recorded 16 h later. CK-MB returned to concentrations
<10 pg/L within 72 h.
The major clinical application of the MB isoenzyme of
creatine kinase (CK, EC 2.7.3.2) is the assessment of acute
myocardial infarction (AMI) (1,2).1 To take full advantage
of the increase of the cardiac isoenzyme in the first hours
after onset of symptoms, a rapid, practical, and sensitive
method for measuring CK-MB in blood is needed.
We report here an analytical and clinical evaluation of
the Stratus#{174}system in determining CK-MB in serum
specimens. The Stratus assay procedure is based on radial
immunopartition (3-7). In the CK-MB method, the solid
phase consists of tabs of glass-fiber filter paper containing a
pre-immobilized monoclonal anti-CK-MB antibody. The
patient’s sample is first applied directly to the central
“reaction zone” of the tab, allowing CK-MB to bind to the
solid-phase-bound antibody. Then, a buffered solution con-
taining enzyme-labeled Fab’ fragments of an anti-CK-BB
monoclonal antibody is applied, initiating “sandwich” for-
mation. Finally, a wash buffer containing a fluorogenic
substrate is applied, eluting unbound conjugate to the tab
periphery. The bound enzyme conjugate is quantified by
measuring the rate of increase in fluorescence. The Stratus
system, which presents the advantage of full automation,
yields quantitative results in 8 mm.
MaterIals and Methods
Instrumentation
Details of the design and operation of the Stratus radial
partition fluorometric immunoassay analyzer (Dade Divi-
Department of Clinical Chemistry, University of Liege, CHU-
B35, Domaine Universitaire du Sart Tilman, B-4000 Liege, Bel-
gium.
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sion, Baxter Inc., Miami, FL 33152) appear elsewhere (8).
No special modification of the instrument was required for
the CK-MB assay.
Procedures
CK-MB determination. We determined CK-MB by radial
immunopartition, using the Stratus analyzer. The CK-MB
fluorometric enzyme immunoassay kit (Dade) contains the
following:
CK-MB antibody tabs.A solution of mouse monoclonal
antibody specific for CK-MB is complexed onto the surface
of glass-fiber filter paper by the addition of goat antibody
specific for the Fe portion of mouse IgG.
Enzyme-labeled anti-CK. Calf intestinal alkaline phos-
phatase (EC 3.1.3.1) is covalently linked to mouse mono-
clonal anti-CK-BB Fab’. The conjugate is solubilized in
2-[(carbamoylmethyl)anuno]ethane sulfonic acid buffer
(pH 7.0).
Substrate wash solution. The fluorogenic substrate con-
sists of 4-methylumbelliferyl phosphate (1 mmol/L) in a
diethanolamine buffer (pH 9.0). The cleavage of the phos-
phate group from 4-methylumbelliferyl phosphate, cata-
lyzed by alkaline phosphatase, results in the production of
4-methylumbelliferone.
CK-MB calibrators. The lyophilized calibrators, when
reconstituted, contain human-heart CK-MB concentra-
tions of approximately 0, 4, 10, 25, 60, and 125 pg/L in
human serum.
Comparison method. We used a solid-phase two-site
iminunoenzymometric assay (Tandem-E CKMB H; Hy-
britech Europe S.A., Sart Tilman, Liege, Belgium) (9), with
the Hybritech “Photon” photometer. In this technique,
samples containing CK-MB are reacted with a plastic-bead
solid phase that is coated with a monoclonal antibody
directed toward the B subunit of CK-MB, and with an
enzyme-labeled monoclonal antibody directed toward the
M subunit of the molecule. After formation of the solid-
phaselCK-MB/labeled-antibody “sandwich,” the bead is
washed, then incubated with enzyme substrate (p-nitro-
phenyl phosphate). The amount of substrate turnover,
determined colorimetrically, is directly proportional to the
concentration of CK-MB in the test sample.
In some specimens, we also determined the CK-MB
content after separation by discontinuous electrophoresis
on polyacrylamide gel (Protean TM II Slab Cell; Bio-Rad
Labs., Richmond, CA). We applied 20 L of serum and
performed the electrophoresis at 4 #{176}Cfor 5 h at 400 V. The
isoenzymes, made visible by specific CK staining, were
measured densitometrically.
Total CK determination. We used an optimized spectro-
photometric method (Enzyline#{174}CK NAC; BioM#{233}rieux,
Lyon, France) to measure total CK at 37#{176}C(reference
limits 0-120 UIL) with an automated analyzer (Eris 6170;
Olympus-Eppendorf, Hamburg, F.R.G.).
Evaluation of imprecision. Two pools of fresh patients’
sera (low- and high-concentration pools) were aliquoted
and frozen, then assayed to evaluate within-run and be-
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tween-run precision. During this part of the study, we
calibrated the Stratus system once a week.
Evaluation of linearity. Two serum samples with high
CK-MB concentration were diluted (in successive twofold
dilutions to a 64-fold dilution) with a serum poo1 containing
no CK-MB (as confirmed by electrophoresis). The resulting
samples, which covered the whole measuring range of
CK-MB, were measured in duplicate.
Method comparisons. We collected 115 serum specimens
from patients admitted to the University Hospital of Liege
and for whom CK-MB had been requested on a routine
basis. These specimens were assayed with the Stratus
CK-MB method and with the comparison method.
Interference studies. Interference by hemoglobin was
studied by adding increasing amounts of hemolysate to a
serum specimen with low CK-MB content (3.3 1gfL) up to
a maximum concentration of hemoglobin of 3.4 g/L, and
assaying. We tested interference by bilirubin by mixing
two fresh serum samples (one containing 4 mg of bilirubin
and 4.5 ,ugof CK-MB per liter, the other 352mg ofbilirubin
and 0.3 ,ugof CK-MB per liter) to prepare four specimens,
and assaying. Interference by rheumatoid factor was tested
with the same experimental model by mixing two fresh
serum samples (one with no rheumatoid factor and 29 jg of
CK-MB per liter, the other with 1230 mt.units of rheuma-
toid factor and 0.9 pg of CK-MB per liter). In these assays,
the maximum concentrations of bilirubin and rheumatoid
factor were 176 mgIL and 615 mt. unitsfL, respectively.
By combining in various proportions three serum sam-
ples with widely differing contents of total CK and CK-MB,
we prepared six serum specimens with total CK activities
increasing stepwise from 506 to 3545 UIL, but with a
nearly constant CK-MB content (18.2 to 20.0 pg/L). The
relative proportions of CK-MM and CK-MB in these six
specimens, and the absence of CK-BB, were confirmed by
electrophoresis. We then assayed each specimen by the
Stratus technique and by the comparison method, without
dilution.
Clinical Evaluation
Healthy subjects. We investigated 105 blood donors, 64
men (mean age ±SD: 43 ± 12 years) and 41 women (38 ±
9 years).
Acute myocardial infarction patients. We studied 18 pa-
tients, ages 30-69 years (mean 57, SD 9 years), who were
admitted to the University Hospital, Liege, Belgium. AMI
was diagnosed on the basis of a history of severe chest pain
and electrocardiographic evidence of localized injury with
typical ST-segment elevations. Total CK activity and CK-
MB concentration were determined at admission, then
every 4 h for 36 h and every 12 h thereafter until 72 h after
admission. To determine the evolution of serum CK-MB
after AMI in a homogeneous group of patients, we assayed
samples from 11 subjects who had reached the coronary
care unit within 4 h after the onset of the symptoms and
whose total CK activities at admission were <150 UIL.
Seven of these patients had received a fibrinolytic ther-
apy (with streptokinase); the other four were treated with
intravenous heparmn.
Results
Precision of the assay. We determined precision proffles
from 20 determinations in the same run for the within-run
tests, and from 20 consecutive determinations on different
days for the between-run tests. Within-assay CVs were
4.2% and 5.5% and between-assay CVs were 3.4% and 8.4%
for two pooled-serum specimens containing 48 and 21 pg of
CK-MB per liter, respectively. The standard deviations
ranged from 1.2 to 2.0 pg/L.
Assessment of linearity. The equations derived from the
regression/correlation analysis of mean found values (y) vs
calculated values(x)werey = 0.997x + 1.58(r = 0.999) for
the first sample investigated (from 1.5 through 94.0 pgfL, n
= 6) and y = 0.949x + 0.45 (r = 0.999) for the other one
(from 1.4 through 89.6 pg/L, n = 6). The minimum detect-
able concentration (mean + 2SD of zero standard, 20
replicates) was 0.2 pg/L.
Analytical recovery. Analytical recovery of CK-MB,
added at concentrations of 17 and 34 ,ug/L to two serum
specimens containing 0.4 and 11.3 pg of CK-MB per liter,
averaged 99.7% (range 91% to 104%).
Correlation between immunopartition (y) and immunoen-
zymometric assay (x). In the 115 serum specimens investi-
gated,the CK-MB concentrations ranged from 0 to 108
j.tg/L (Stratus technique). The results by both methods were
related by the regression equation y = 0.744x + 1.15 (r =
0.98).
Interference. We saw no interference for hemoglobin
concentrations up to 2.25 g/L. At 3.4 g/L, there was a very
mild positive interference (CK-MB values 0.3 pg higher
than expected). Assay of the hemolysate alone (6.75 g of
hemoglobin per liter, absence of CK-MB confirmed by
electrophoresis) gave a CK-MB value of 3.7 pg/L. Bilirubin
and rheumatoid factor gave no detectable interference up
to 178 mg/L and 615 mt.units/L, respectively. Addition of
CK-MM up to 3500 U/L altered none of the CK-MB results
determined by the Stratus technique (92-106% of the
expected CK-MB value). In contrast, the CK-MB values
measured by the comparison technique were regularly
decreased in the specimens containing CK-MM >1100 U/L;
the specimen containing CK-MM at 3500 U/L gave only
39% of its expected CK-MB value.
Reference interval. In the 105 blood donors investigated,
the mean serum CK-MB concentration was 1.9 pg/L (SD
1.3 pg/L). Men demonstrated slightly, but not significantly,
higher CK-MB concentrations than women (2.0 ± 1.3 vs
1.8 ± 1.2 pg/L). Using the nonparametric method of per-
centile estimation (10), we calculated the normal reference
interval for serum CK-MB to be 0-6 pgfL.
Acute myocardial infarction patients. We observed a
typical increase and decrease pattern for serum total CK
activities in the 11 patients with short delays in admission.
Total CK peak activities ranged from 841 to 4140 UIL in
the streptokinase-treated group (n = 7) and from 1421 to
2400 UIL in the patients who received intravenous heparin
(n = 4).
For the streptokinase-treated patients, the mean CK-MB
concentration in serum was 4.5 (SD 1.8) pgfL (mean ± SD)
at admission, but increased rapidly during the following
hours and averaged 97.9 pg/L 8 h after admission (Figure
1). At peak (16 h after admission), CK-MB concentrations
ranged from 38to 295 pg/L (mean 119, SD 94 pg/L). On day
3, the mean CK-MB concentration had decreased to 3.2
pgIL (range 0-9.7 pgfL). In the patients who received
heparin, CK-MB reached its peak 20 h after admission, 4 h
later than in the streptokinase-treated group. After hep-
arm treatment, however, the amplitude of the changes was
similar to those observed after fibrinolytic therapy, maxi-
mum concentrations ranging from 45 to 308 pg/L (mean
126, SD 103 pg/L). After 72 h, the heparin-treated patients
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Fig. 1. Evolution of the mean serum CK-MB concentration, as
measuredwith the Stratus assay, and of the mean CK-MB index
duringthe first 72 h of hospitalizationin AMI patientswith short
delaysin admission(fibrinolytic therapy)
demonstrated a mean CK-MB concentration of 9.3 pg/L
(range 0-20 pgfL).
At each measurement time, we also calculated the index
[(CK-MBItotal CK) x 1001 corresponding to the mass
concentration of CK-MB in micrograms per 100 units of
total CK activity in the sample. For the streptokinase-
treated group, the index values ranged from 2.6 to 8.1
(mean 4.7) at admission. A progressive increase was re-
corded in the following hours (Figure 1). The curve of the
mean index values reached its maximum 16 h after admis-
sion (mean 6.8, range 4.3-9.0). Mean index values de-
creased to 4.3 and 0.9, respectively, 32 and 72 h after
admission. In the patients who received heparmn, we ob-
served a similar evolution of the index, maximum values
(range 4.1-19.5, mean 7.9) being recorded 20 h after admis-
sion.
DIscussIon
In this study,we investigated the analytical performance
of the Stratus CK-MB method. Precision studies demon-
strated within-run and between-run CVs <5.5% and 8.5%,
respectively. The limit of detection for CK-MB was 0.2
pg/L; the linearity of the technique, evaluated from 1.4
through 95.5 pg/L, was excellent. Results by the Stratus
technique correlated well with those by the Hybritech
Tandem-E CK-MB H technique (r = 0.98). There was no
detectable interference by hemoglobin, bilirubin, or rheu-
matoid factor up to 2.25 g/L, 178 mg/L, and 615 mt.units/L,
respectively. With the Stratus technique, CK-MB can be
determined in the presence of large amounts of CK-MM (at
least up to 3500 U/L). This allows CK-MB to be measured
in specimens with high total CK content without dilution.
The method has also the added advantage of quickness (8
mm for a result if the calibration curve is stored) and full
assay automation.
Reference values determined by the Stratus technique
for serum CK-MB were 0-6 jtg/L, which compares well
with those obtained by others using an immunoenzymo-
metric assay (9). Serial determinations performed in AMI
patients showed the typical increase and decrease in CK-
MB during the first 72 h after the attack. Within 24 h of
admission, CK-MB increased to concentrations exceeding,
on average, more than 20 times the upper limit of the
reference interval. In most cases, the value had returned to
2 normal by day 3. Confirming previous results (11), CK-MB
peaked earlier in the patients treated by streptokinase
than in those who received heparin. The amplitude of the
changes was, however, similar in the two groups of pa-
tients. In the patients investigated, the mean value of the
CK-MB index, which expressed the CK-MB concentration
as a percent of total CK activity, exceeded 4 during the first
32 h after admission.
In conclusion, we have validated a rapid, convenient
radial partition immunoassay for CK-MB in serum and
have demonstrated its clinical applicability when used at a
coronary-care unit for diagnostic evaluation of AMI pa-
tients.
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